Robert Popovian, PharmD, MS, Discusses Biosimilar Progress and Education in the United States
January 12th 2022As chief science policy officer for Global Healthy Living Foundation, Robert Popovian, PharmD, MS, has a bird’s-eye view of some of the central issues of biosimilar access in the United States.
Ivo Abraham, PhD, Discusses G-CSF Biosimilars, Such as Neulasta Onpro
October 11th 2021Ivo Abraham, PhD, a professor with University of Arizona Health Sciences in the Department of Pharmacy Practice, outlines the current trajectory and savings potential for granulocyte-colony stimulating factor (G-CSF) biosimilars and Neulasta Onpro (pegfilgrastim).
Kashyap Patel, MD, Highlights the Struggles of Using Pegfilgrastim Biosimilars During the Pandemic
September 26th 2021As COVID-19 cases continue to rise in many states, Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care Associates, provides insight into how biosimilar pegfilgrastims can help reduce costs; however, not all payers are on board.
AAO Reacts to Ranibizumab Biosimilar Approval
September 23rd 2021The Center for Biosimilars® spoke with George Williams, MD, clinical spokesperson for the American Academy of Ophthalmology (AAO), about the FDA’s recent approval of Byooviz (ranibizumab), the first biosimilar specifically approved for treatment of eye diseases.
Axinn’s Landmon Provides an Expert Legal Opinion on HHS’ Drug Price Strategy
September 22nd 2021The HHS plan ordered up by President Biden for combatting high drug prices is a hodgepodge of ideas that have long circulated in Washington, DC, but can any of them be made to stick? An intellectual property and FDA policy expert, Chad Landmon, JD, shares his perspective.
Not So Different: How Biosimilar Companies Are Stepping Up Their Game to Compete Against Originators
September 19th 2021Kirollos Hanna, PharmD, from the University of Minnesota Medical Center, discusses some of the tactics that biosimilar companies are employing in order to level the playing field and better compete against originator companies.
Chad Pettit, MBA, Discusses Amgen’s Biosimilar Trends Report and the Future of Biosimilars in the US
August 18th 2021Chad Pettit, MBA, executive director of Marketing and the Global Biosimilars commercial lead for Amgen, discussed the company’s 2021 Biosimilar Trends Report and his projections for the future of the biosimilars market.
Neal Dave, PharmD, Discusses What Clinics Need to Do to Ensure Biosimilars Are Cost-efficient
August 9th 2021Health care systems need to consistently reevaluate whether the biosimilars they utilize are the most cost-effective, Neal Dave, PharmD, the executive director of pharmacy at Texas Oncology, explains.
Cate Lockhart: Putting the US Biosimilar Industry in Perspective
May 31st 2021In part 2 of this interview, Cate Lockhart, PharmD, PhD, executive director of the Biologics and Biosimilar Collective Intelligence Consortium, discusses the potential for interchangeable insulin biosimilars and the challenges of obtaining reliable and optimized real world data.
Cate Lockhart: Is There Hope for a Robust Biosimilar Industry in the United States?
May 26th 2021In part 1 of this interview, Cate Lockhart, executive director of the Biologics and Biosimilar Collective Intelligence Consortium, details some of her expectations for further growth of the US biosimilar market.
Magellan Rx Pharmacists Explore the Payer Perspective on Oncology Biosimilars
April 18th 2021Rebecca Borgert, PharmD, BCOP, and Jim Rebello, PharmD, from Magellan Rx Management talk about how market trends, payer formulary decisions, and international successes are shaping today's biosimilars industry.